LADX — LadRx Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
U.S. STOCKS ON THE MOVE-Axovant, Benitec, Groupon, KemPharm, Nano Dimension
Brief: CytRx Announces Closing Of $7.0 Mln Registered Direct Offering
Brief: Cytrx Announces $7.0 Million Registered Direct Offering
Brief: Cytrx Reports First Quarter Loss Of $0.15 Per Share
Brief: CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical Trials
Brief: Cytrx Corp Announces Its Entry Into A Definitive Agreement With Destum Partners
Brief: Cytrx announces new shareholder initiatives
Brief: Cytrx reports strategic realignment of clinical development team
Brief: Cytrx Corp announces reverse stock split
Brief: Cytrx corp says Nasdaq has granted co's request for a continued listing
Brief: Cytrx highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions
Brief: CytRx Corp provides business update and highlights future plans
Brief: CytRx corp says Glass Lewis & Co recommends CytRx stockholders vote "for" proposed reverse stock split
Brief: CytRx Corp announces amendment to definitive proxy statement for upcoming special meeting
Brief: Cytrx reports Q2 loss per share $0.10
Brief: Cytrx Corp announces Global Strategic License With Nantcell for Aldoxorubicin
Brief: Cytrx reports Q1 loss per share $0.10
Brief: Cytrx Corp prices $15 mln public offering of common stock
Brief: Cytrx says FDA agreement on regulatory pathway for Aldoxorubicin